Completed PHASE2 INTERVENTIONAL 2-arm NCT01220050

Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism (APPLE)

A PROSPECTIVE, PILOT, CROSS-OVER STUDY TO ASSESS THE EFFICACY OF PARICALCITOL IN REDUCING PARATHYROID HORMONE LEVELS AND AMELIORATING MARKERS OF BONE REMODELLING IN RENAL TRANSPLANT RECIPIENTS WITH SECONDARY HYPERPARATHYROIDISM

Sponsor: Mario Negri Institute for Pharmacological Research

Conditions Renal Transplant Secondary Hyperparathyroidism

Interventions Paricalcitol Standard therapy

Updated 5 times since 2017 Last updated: Feb 21, 2013 Started: Sep 30, 2009 Primary completion: Jul 31, 2012 Completion: Feb 28, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Renal Transplant and Secondary Hyperparathyroidism, this trial is completed. The trial is conducted by Mario Negri Institute for Pharmacological Research and has accumulated 5 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mario Negri Institute for Pharmacological Research

Data source: Mario Negri Institute for Pharmacological Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ranica, Italy